Cited by 399Diabetes Treatment and ManagementDiabetes Management and ResearchPharmacology and Obesity Treatment

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Komoroski, B, Vachharajani, N, Feng, Y, Li, L, Kornhauser, D, Pfister, M·2009·Clinical Pharmacology & Therapeutics

DOI 10.1038/clpt.2008.250

Open this paper in CoChat — free account

Abstract

Dapagliflozin, administered to patients in once-daily oral doses, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks the reabsorption of glucose from urine into the blood. This 14-day study randomized patients with type 2 diabetes mellitus (T2DM) to four treatment groups receiving daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin or placebo, in order to evaluate glucosuria and glycemic parameters. Significant reductions in fasting serum glucose (FSG) were observed on day 2 with 100 mg dapagliflozin (-9.3%, P < 0.001), and dose-dependent reductions were observed on day 13 with the 5-mg (-11.7%; P < 0.05), 25-mg (-13.3%; P < 0.05), and 100-mg (-21.8%; P < 0.0001) doses as compared with placebo. Significant improvements in oral glucose tolerance test (OGTT) were observed with all doses on days 2 and 13 (P < 0.001 as compared with placebo). On day 14, urine glucose values were 36.6, 70.1, and 69.9 g/day for the 5-, 25-, and 100-mg doses (as compared with no change for placebo), which were slightly lower than those on day 1. This was attributed to the decrease in filtered glucose load following improved glycemic control. Dapagliflozin produced dose-dependent increases in glucosuria and clinically meaningful changes in glycemic parameters in T2DM patients.

Integrity signals

Registry

Crossref · 10.1038/clpt.2008.250

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
Rossetti, L., Smith, D. J., Shulman, G. I., Papachristou, D. N., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 824
Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Han, S., Hagan, D. L., Taylor, J. R., Xin, L., Meng, W., Biller, S. A., Wetterau, J. R., Washburn, W. N., & Whaley, J. M. (2008) · Diabetes · doi:10.2337/db07-1472 · Cited by 423
Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria
Santer, R., Kinner, M., Lassen, C. L., Schneppenheim, R., Eggert, P., Bald, M., Brodehl, J., Daschner, M., Ehrich, J. H. H., Kemper, M., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092790.89332.d2 · Cited by 304
Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose Level
Katsuno, K., Fujimori, Y., Takemura, Y., Hiratochi, M., Itoh, F., Komatsu, Y., Fujikura, H., & Isaji, M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110296 · Cited by 268
Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal
Andrews, W. J., Vasquez, B., NAGULESPARAN, M., Klimeś, I., Foley, J. E., Unger, R. H., & Reaven, G. M. (1984) · Diabetes · doi:10.2337/diab.33.7.634 · Cited by 194
Candidal Vulvovaginitis
Sobel, J. D. (1993) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-199303000-00021 · Cited by 154
Long-term outcome of renal glucosuria type 0: the original patient and his natural history
Scholl‐Bürgi, S., Santer, R., & Ehrich, J. H. H. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh366 · Cited by 104

Flagged first, then by citations

Show all 20 references

Research works printed but not linked: 3

Chen J, 2008, Diabetes, 57, A682
Oemar B.S, 1987, Clin. Nephrol, 27, 156
Gibb D, 1995, NZ Med. J, 108, 252

Sorted by citations

Items 101–200 of 399

Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients
Dobbins, R. L., O’Connor‐Semmes, R., Kapur, A., Kapitza, C., Golor, G., Mikoshiba, I., Tao, W., & Hussey, E. K. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01462.x · Cited by 80
Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial
Henry, R. R., Strange, P., Zhou, R., Pettus, J., Shi, L., Zhuplatov, S. B., Mansfield, T. A., Klein, D. J., & Katz, A. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0052 · Cited by 81
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
Zhang, Y., Thai, K., Kepecs, D. M., & Gilbert, R. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0144640 · Cited by 79
Epigenetic modification and therapeutic targets of diabetes mellitus
Singh, R., Chandel, S., Dey, D., Ghosh, A., Roy, S., Ravichandiran, V., & Ghosh, D. (2020) · Bioscience Reports · doi:10.1042/bsr20202160 · Cited by 85
Novel l -Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes
Goodwin, N. C., Mabon, R., Harrison, B. A., Shadoan, M. K., Almstead, Z. Y., Xie, Y., Healy, J. P., Buhring, L., DaCosta, C. M., Bardenhagen, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900951n · Cited by 78
Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial
Strojek, K., Yoon, K., Hrubá, V., Sugg, J. E., Langkilde, A. M., & Parikh, S. J. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0072-0 · Cited by 75
A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus
Ikeda, S., Takano, Y., Cynshi, O., Tanaka, R., Christ, A. D., Boerlin, V., Beyer, U., Beck, A., Ciorciaro, C., Meyer, M., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12538 · Cited by 73
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes
Babu, A. R., Kim, S., & Babu, A. R. (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22545 · Cited by 71
New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
Dekkers, C. C. J., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-0992-6 · Cited by 76
Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
Schwartz, S. L., Akinlade, B., Klasen, S., Kowalski, D. L., Zhang, W., & Wilpshaar, W. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0012 · Cited by 70
Targeting glucose metabolism for healthy aging
Brewer, R. A., Gibbs, V. K., & Smith, D. L. (2016) · Nutrition and Healthy Aging · doi:10.3233/nha-160007 · Cited by 69
Inhibition of the sodium glucose co‐transporter‐2: its beneficial action and potential combination therapy for type 2 diabetes mellitus
Chen, L., & Leung, P. S. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12064 · Cited by 67
Carcinogenicity Risk Assessment Supports the Chronic Safety of Dapagliflozin, an Inhibitor of Sodium–Glucose Co-Transporter 2, in the Treatment of Type 2 Diabetes Mellitus
Reilly, T. P., Graziano, M. J., Janovitz, E. B., Dorr, T. E., Fairchild, C. R., Lee, F. Y., Chen, J., Wong, T., Whaley, J. M., & Tirmenstein, M. A. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0053-3 · Cited by 63
Twice‐daily dapagliflozin co‐administered with metformin in type 2 diabetes: a 16‐week randomized, placebo‐controlled clinical trial
Schumm‐Draeger, P. ‐., Burgess, L. J., Koranyi, L. I., Hrubá, V., Hamer-Maansson, J. E., & de Bruin, T. W. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12387 · Cited by 65
Lowering plasma glucose concentration by inhibiting renal sodium–glucose cotransport
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12244 · Cited by 63
Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives
Maccari, R., & Ottanà, R. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00867 · Cited by 67
Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options
Chiu, C., Du, Y., Ou, H., & Beverly, E. A. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s53482 · Cited by 67
Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin
Kasichayanula, S., Chang, M., Liu, X., Shyu, W.-C., Griffen, S. C., LaCreta, F. P., & Boulton, D. W. (2012) · Advances in Therapy · doi:10.1007/s12325-011-0098-x · Cited by 62
Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management
Cefalu, W. T., Buse, J. B., Prato, S. D., Home, P., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 62
Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
Kaku, K., Maegawa, H., Tanizawa, Y., Kiyosue, A., Ide, Y., Tokudome, T., Hoshino, Y., JISIN, Y., & Langkilde, A. M. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0086-7 · Cited by 61
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
Whaley, J. M., Tirmenstein, M. A., Reilly, Poucher, Saye, Parikh, & List (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s22503 · Cited by 60
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
Yavin, Y., Mansfield, T. A., Ptaszynska, A., Johnsson, K. M., Parikh, S. J., & JOHNSSON, E. K. (2016) · Diabetes Therapy · doi:10.1007/s13300-015-0150-y · Cited by 62
The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
Delanaye, P., & Scheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101285 · Cited by 64
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial
Tan, S., Ignatenko, S., Wagner, F. D., Dokras, A., Seufert, J., Zwanziger, D., Dunschen, K., Zakaria, M., Huseinovic, N., Basson, C. T., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14495 · Cited by 57
Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes
Hardman, T. C., & Dubrey, S. W. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0004-1 · Cited by 57
SGLT2 inhibitors act from the extracellular surface of the cell membrane
Ghezzi, C., Hirayama, B. A., Gorraitz, E., Loo, D. D. F., Liang, Y. T., & Wright, E. M. (2014) · Physiological Reports · doi:10.14814/phy2.12058 · Cited by 57
Hypothalamic POMC Deficiency Improves Glucose Tolerance Despite Insulin Resistance by Increasing Glycosuria
Chhabra, K. H., Adams, J. M., Fagel, B., Lam, D. D., Qi, N., Rubinstein, M., & Low, M. J. (2015) · Diabetes · doi:10.2337/db15-0804 · Cited by 55
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 57
Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
Veltkamp, S. A., Kadokura, T., Krauwinkel, W. J. J., & Smulders, R. A. (2011) · Clinical Drug Investigation · doi:10.1007/bf03256922 · Cited by 55
Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling
Shentu, Y., Li, Y., Xie, S., Jiang, H., Sun, S., Lin, R., Chen, C., Bai, Y., Zhang, Y., Zheng, C., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107374 · Cited by 55
Single‐Dose Pharmacokinetics and Pharmacodynamics of Sergliflozin Etabonate, a Novel Inhibitor of Glucose Reabsorption, in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus
Hussey, E. K., Clark, R. V., Amin, D. M., Kipnes, M. S., O'Connor‐Semmes, R. L., O'Driscoll, E. C., Leong, J., Murray, S. C., Dobbins, R. L., Layko, D., et al. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009351879 · Cited by 55
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
Narendran, P., & Saeed, M. A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s50963 · Cited by 58
Dapagliflozin: A Novel Sodium‐Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Shah, N. K., Deeb, W., Choksi, R. R., & Epstein, B. J. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1010 · Cited by 52
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes
Liao, X., Wang, X., Li, H., Li, L., Zhang, G., Yang, M., Yuan, L., Liu, H., Yang, G., & Gao, L. (2016) · Scientific Reports · doi:10.1038/srep32887 · Cited by 54
Self-citation
Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
Lu, Y., Griffen, S. C., Boulton, D. W., & Leil, T. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00274 · Cited by 52
Aquaporin 11 insufficiency modulates kidney susceptibility to oxidative stress
Atochina‐Vasserman, E. N., Biktasova, A., Абрамова, Е. В., Cheng, D., Polosukhin, V. V., Tanjore, H., Takahashi, S., Sonoda, H., Foye, L., Venkov, C. D., et al. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00344.2012 · Cited by 52
Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells
Pirklbauer, M., Schupart, R., Fuchs, L., Staudinger, P., Corazza, U., Sallaberger, S., Leierer, J., Mayer, G. J., & Schramek, H. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00431.2018 · Cited by 52
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
Kapur, A., O'Connor‐Semmes, R. L., Hussey, E. K., Dobbins, R. L., Tao, W. X., Hompesch, M., Smith, G. A., Polli, J. W., James, C. D., Mikoshiba, I., et al. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-26 · Cited by 51
Sotagliflozin: a dual sodium‐glucose co‐transporter‐1 and ‐2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus
Sims, H., Smith, K. H., Bramlage, P., & Minguet, J. (2018) · Diabetic Medicine · doi:10.1111/dme.13645 · Cited by 53
Eemergence of Promising Therapies in Diabetes Mellitus
Akkati, S., Sam, K. G., & Tungha, G. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010376972 · Cited by 49
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
Fioretto, P., Mansfield, T. A., Ptaszynska, A., Yavin, Y., JOHNSSON, E. K., & Parikh, S. J. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0382-1 · Cited by 51
Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.019 · Cited by 49
Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus
Takebayashi, K., & Inukai, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3112w · Cited by 49
SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
Moses, R. G., Colagiuri, S., & Pollock, C. A. (2014) · Australasian Medical Journal · doi:10.4066/amj.2014.2181 · Cited by 47
Effect of kidney disease on glucose handling (including genetic defects)
Calado, J., Santer, R., & Rueff, J. (2011) · Kidney International · doi:10.1038/ki.2010.510 · Cited by 46
Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamus-specific Pomc knockout mice
Chhabra, K. H., Morgan, D. A., Tooke, B. P., Adams, J. M., Rahmouni, K., & Low, M. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.07.005 · Cited by 46
Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats
Nagata, T., Fukazawa, M., Honda, K., Yata, T., Kawai, M., Yamane, M., Murao, N., Yamaguchi, K., Kato, M., Mitsui, T., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2012 · Cited by 45
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice
Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.06.004 · Cited by 45
SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
Misra, M. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01574.x · Cited by 45
Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
Vivian, E. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140168 · Cited by 45
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis
Cho, Y. K., Kim, Y., & Jung, C. H. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21061 · Cited by 45
Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
Li, Y., Li, H., Li, H., Bui, A., Chang, M., Liu, X., Kasichayanula, S., Griffen, S. C., LaCreta, F. P., & Boulton, D. W. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.017 · Cited by 43
SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
Zhou, Y., Fan, J., Zheng, C., Yin, P., Wu, H., Li, X., Luo, N., Yu, X., & Chen, C. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.106 · Cited by 43
SGLT2 inhibitors: glucuretic treatment for type 2 diabetes
Bailey, C. J., & Day, C. (2010) · The British Journal of Diabetes · doi:10.1177/1474651410377832 · Cited by 45
Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes
Bacha, F. F., & Bartz, S. K. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12337 · Cited by 42
Learning From Glycosuria
Ferrannini, E. (2011) · Diabetes · doi:10.2337/db10-1667 · Cited by 41
Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
Chung, S., Kim, S., Son, M., Kim, M., Koh, E. S., Shin, S. J., Ko, S., & Kim, H. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00271 · Cited by 40
Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats
Kim, S., Jo, C. H., & Kim, G. (2019) · Hypertension Research · doi:10.1038/s41440-019-0326-3 · Cited by 40
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND
Sen, T., Scholtes, R. A., Greasley, P. J., Cherney, D. Z. I., Dekkers, C. C. J., Vervloet, M. G., Danser, A. H. J., Barbour, S. J., Karlsson, C., Hammarstedt, A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14729 · Cited by 39
The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
Muscoli, S., Barillà, F., Tajmir, R., Meloni, M., Della‐Morte, D., Bellia, A., Daniele, N. D., Lauro, D., & Andreadi, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081730 · Cited by 39
Dapagliflozin: more than just another oral glucose-lowering agent?
Katsiki, N., Παπάνας, Ν., & Mikhailidis, D. P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.539558 · Cited by 39
Dapagliflozin for prednisone‐induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease
Gerards, M. C., Venema, G., Patberg, K. W., Kross, M., van Loon, B. J. P., Hageman, I. M. G., Snijders, D., Brandjes, D. P. M., Hoekstra, J. B. L., Vriesendorp, T. M., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13209 · Cited by 39
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
Johnsson, K. M., JOHNSSON, E. K., Mansfield, T. A., Yavin, Y., Ptaszynska, A., & Parikh, S. J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1153941 · Cited by 39
A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus
Hohendorff, J., Szopa, M., SKUPIEN, J. K., Kapusta, M., Zapała, B., Płatek, T., Mrozińska, S., Parpan, T., Głodzik, W., Ludwig-Galezowska, A. H., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1341-2 · Cited by 42
Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis
Refardt, J. C., Winzeler, B. F., Meienberg, F., Vogt, D., & Christ‐Crain, M. (2017) · International Journal of Endocrinology · doi:10.1155/2017/7815690 · Cited by 41
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
Hussey, E. K., Kapur, A., O'Connor‐Semmes, R. L., Tao, W. X., Rafferty, B., Polli, J. W., James, C. D., & Dobbins, R. L. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-25 · Cited by 38
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Tahrani, A. A., & Barnett, A. H. (2010) · Diabetes Therapy · doi:10.1007/s13300-010-0007-3 · Cited by 37
Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes
Heo, C. U., & Choi, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030393 · Cited by 40
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
Takata, T., & Isomoto, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094374 · Cited by 37
Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study
Carlson, G. F., Tou, C., Parikh, S. J., Birmingham, B. K., & Butler, K. A. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0003-2 · Cited by 38
Role of Genetic Variation in the Human Sodium–Glucose Cotransporter 2 Gene ( SGLT2 ) in Glucose Homeostasis
Enigk, U., Breitfeld, J., Schleinitz, D., Dietrich, K., Halbritter, J., Fischer‐Rosinsky, A., Enigk, B., Müller, I., Spranger, J., Pfeiffer, A. F. H., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.69 · Cited by 43
Dapagliflozin for the Treatment of Type 2 Diabetes
Anderson, S. L., & Marrs, J. C. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q538 · Cited by 36
Risk of genital and urinary tract infections associated with SGLT‐2 inhibitors as an add‐on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
Yang, H., Choi, E., Park, E., Na, E., Chung, S. Y., Kim, B. G., & Han, S. Y. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.910 · Cited by 36
The Management of Type 2 Diabetic Patients with Hypoglycaemic Agents
Tsang, M.-W. (2012) · ISRN Endocrinology · doi:10.5402/2012/478120 · Cited by 36
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35
Selective Reaction Monitoring of Negative Electrospray Ionization Acetate Adduct Ions for the Bioanalysis of Dapagliflozin in Clinical Studies
Ji, Q., Xu, X., Ma, E., Liu, J., Basdeo, S., Liu, G., Mylott, W. R., Jr., Boulton, D. W., Shen, J. X., Stouffer, B. C., et al. (2015) · Analytical Chemistry · doi:10.1021/ac5037523 · Cited by 34
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
Gu, S., Mu, Y., Zhai, S., Zeng, Y., Zhen, X., & Dong, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165629 · Cited by 35
Effects of the sodium‐glucose cotransporter 2 ( SGLT 2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats
Hoenig, M. E., Clark, M., Schaeffer, D. J., & Reiche, D. (2017) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12467 · Cited by 34
The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
Bjornstad, P., Greasley, P. J., Wheeler, D. C., Chertow, G. M., Langkilde, A. M., Heerspink, H. J. L., & van Raalte, D. H. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.003 · Cited by 41
SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment
Bhartia, M., Tahrani, A. A., & Barnett, A. H. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.348 · Cited by 33
Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus
Tirucherai, G., LaCreta, F. P., Ismat, F. A., Tang, W., & Boulton, D. W. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12638 · Cited by 34
Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
Xiang, B., Zhao, X.-Y., & Zhou, X. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01266-x · Cited by 35
Peritoneal Expression of SGLT-2, GLUT1, and GLUT3 in Peritoneal Dialysis Patients
Schricker, S., Oberacker, T., Fritz, P., Ketteler, M., Alscher, M. D., & Schanz, M. (2021) · Kidney & Blood Pressure Research · doi:10.1159/000520894 · Cited by 37
Dapagliflozin for the Treatment of Type 2 Diabetes
Brooks, A. M., & Thacker, S. M. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m212 · Cited by 32
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry
Sawada, Y., Izumida, Y., Takeuchi, Y., Aita, Y., Wada, N., Li, E., Murayama, Y., Piao, X., Shikama, A., Masuda, Y., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.081 · Cited by 31
Emerging therapies for metabolic diseases—the focus is on diabetes and obesity
Hughes, T. E. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.622 · Cited by 30
Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
Pfister, M., Whaley, J. M., Zhang, L., & List, J. F. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.16 · Cited by 32
Self-citation
Dapagliflozin: Glucuretic action and beyond
Balakumar, P., Sundram, K., & Dhanaraj, S. A. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.008 · Cited by 30
Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study
Ku, E. J., Lee, D., Jeon, H. J., & Oh, T. K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109123 · Cited by 35
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial
Heerspink, H. J. L., Greasley, P. J., Ahlström, C., Althage, M., Dwyer, J. P., Law, G., Wijkmark, E., Lin, M., Mercier, A., Sunnåker, M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad183 · Cited by 30
Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
Pinto, L. C. F., Rados, D. R. V., Remonti, L. R., Viana, M. V., Leitão, C. B., & Gross, J. L. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000440 · Cited by 32
The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis
Hu, S., Lin, C., Cai, X., Zhu, X., Lv, F., Nie, L., & Ji, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.814074 · Cited by 29
Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with Type 2 diabetes mellitus
Gerich, J. E., & Bastien, A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.54 · Cited by 27
A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3‐ O ‐glucuronide in Renal or Hepatic Impairment
van der Walt, J., Hong, Y., Zhang, L., Pfister, M., Boulton, D., & Karlsson, M. (2013) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.20 · Cited by 28
Self-citation
Dapagliflozin for the treatment of type 2 diabetes
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.812632 · Cited by 30
Short-term effects of canagliflozin on glucose and insulin responses in insulin dysregulated horses: A randomized, placebo-controlled, double-blind, study
Lindåse, S. S., Nostell, K. E. A., Forslund, A. H., Bergsten, P., & Bröjer, J. T. (2023) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16906 · Cited by 29
Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors
Patel, A. K., & Fonseca, V. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0095-5 · Cited by 27
Dapagliflozin: a review on efficacy, clinical effectiveness and safety
Paisley, A. N., Yadav, R., Younis, N., Rao‐Balakrishna, P., & Soran, H. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740009 · Cited by 27
Non‐insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions
Wright, L. A.-C., & Hirsch, I. B. (2019) · Diabetic Medicine · doi:10.1111/dme.13941 · Cited by 26
Identification of novel small molecule inhibitors for solute carrier SGLT1 using proteochemometric modeling
Burggraaff, L., Oranje, P., Gouka, R. J., Pijl, P., Geldof, M., van Vlijmen, H., IJzerman, A. P., & van Westen, G. J. P. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0337-8 · Cited by 26

Authors: Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M.
Affiliations: Bristol-Myers Squibb (United States) (US)
Corresponding author: Pfister, M
ORCID: Pfister, M
Venue: Clinical Pharmacology & Therapeutics
Publisher: Wiley
Published: 2009-01-07
Volume: 85
Issue: 5
Pages: 513-519
ISSN: 0009-9236 (ISSN-L)
1532-6535
DOI: 10.1038/clpt.2008.250
OpenAlex: W2000047428
Cited by: 396
References: 20
Citations by year: 2026: 14 · 2025: 13 · 2024: 16 · 2023: 14 · 2022: 16 · 2021: 17 · 2020: 14 · 2019: 22 · 2018: 18 · 2017: 19 · 2016: 24 · 2015: 18 · 2014: 39 · 2013: 39 · 2012: 32
FWCI: 27.68
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords: dapagliflozin, SGLT2 inhibitors, type 2 diabetes, glycemic control, glycosuria, fasting serum glucose, oral glucose tolerance test, dose-dependent effects, urinary glucose excretion
MeSH terms: Sodium-Glucose Transporter 2 Inhibitors, Administration, Oral, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucose Tolerance Test, Glucosides, Glycosuria, Humans, Hypoglycemic Agents, Male, Middle Aged, Time Factors, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks